Metagenomi, Inc. Common Stock (MGX) has a negative trailing P/E of -0.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -169.86%.
Criteria proven by this page:
Overall SharesGrow Score: 57/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2021 | -2.9 | 0.00 | -1.88 | 251.58 | - |
| 2022 | -8.9 | 0.13 | -5.19 | 22.46 | - |
| 2023 | -5.7 | -0.10 | 1.80 | 8.63 | - |
| 2024 | -1.7 | -0.12 | 0.58 | 2.58 | - |
| 2025 | -0.7 | -0.05 | 0.38 | 2.39 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2021 | $-3.62 | $243K | $-21.44M | -8823.9% |
| 2022 | $-1.16 | $17.2M | $-43.59M | -253.4% |
| 2023 | $-1.82 | $44.76M | $-68.26M | -152.5% |
| 2024 | $-2.36 | $52.3M | $-78.06M | -149.3% |
| 2025 | $-2.36 | $25.21M | $-87.87M | -348.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.12 | $-2.26 – $-2.00 | $23.59M | $21.48M – $25.69M | 3 |
| 2027 | $-1.90 | $-2.55 – $-1.13 | $22.69M | $22.29M – $23.08M | 4 |
| 2028 | $-1.90 | $-2.34 – $-1.47 | $20M | $16.12M – $29.98M | 2 |
| 2029 | $-1.95 | $-3.21 – $-1.46 | $20M | $16.12M – $29.98M | 1 |
| 2030 | $-1.80 | $-2.98 – $-1.35 | $20M | $16.12M – $29.98M | 1 |
